Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
19 Abril 2024 - 6:00AM
Business Wire
Earnings Conference Call and Webcast Will Begin
at 7:00 am (CT)
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical
device and in vitro diagnostic technologies to the healthcare
industry, today announced that second quarter of fiscal year 2024
financial results will be released before the market opens on
Wednesday, May 1.
Management will host a live webcast and conference call at 7:00
a.m. CT (8:00 a.m. ET) on Wednesday, May 1, to discuss the second
quarter fiscal 2024 financial results and accomplishments and host
a question-and-answer session. To access the webcast, please go to
“Events & Presentations” under the “Investors” section of the
Company’s website at
https://surmodics.gcs-web.com/events-and-presentations, and click
on the webcast icon under “Upcoming Events.” To listen to the live
teleconference, please dial 877-407-8293 (international callers may
dial +1 201-689-8349) and provide event ID 13745933.
An audio replay of the conference call will be available
beginning at approximately 11 a.m. CT on Wednesday, May 1, until
approximately 11 a.m. CT on Wednesday, May 15, and can be accessed
by dialing 877‑660‑6853 (international callers may dial
201-612-7415) and entering access ID 13745933. In addition, the
webcast and transcript will be archived on the Company’s website
following the call.
About Surmodics, Inc.
Surmodics is a leading provider of performance coating
technologies for intravascular medical devices and chemical and
biological components for in vitro diagnostic immunoassay tests and
microarrays. Surmodics also develops and commercializes highly
differentiated vascular intervention medical devices that are
designed to address unmet clinical needs and engineered to the most
demanding requirements. This key growth strategy leverages the
combination of the Company’s expertise in proprietary surface
modification and drug-delivery coating technologies, along with its
device design, development, and manufacturing capabilities. The
Company’s mission is to improve the detection and treatment of
disease. Surmodics is headquartered in Eden Prairie, Minnesota. For
more information, visit www.surmodics.com. The content of
Surmodics’ website is not part of this press release or part of any
filings that the company makes with the Securities and Exchange
Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240419153737/en/
Surmodics Investor Inquiries: Jack Powell, Investor Relations
ir@surmodics.com
SurModics (NASDAQ:SRDX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
SurModics (NASDAQ:SRDX)
Gráfica de Acción Histórica
De May 2023 a May 2024